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Abstract
Background: No published systematic reviews have assessed the natural history of colonization with
methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of
colonization has important implications for patient care and infection control policy.
Methods: We performed parallel searches in OVID Medline for studies that reported the time to documented
clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July
2012.
Results: For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3
randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles,
identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936
non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of
initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The
median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the
model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized
patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were
compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for
VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA
would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to
length of study follow-up.
Conclusions: Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent
definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for
persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing
published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to
clearance, however, studies included in this review suggest an increase in documented clearance over time, a result
which is sensitive to duration of follow-up.
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Methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus (VRE) are endemic in
hospital settings and long-term care facilities (LTCF), and
the prevalence of colonization is increasing [1-4]. The
growing pools of colonized, and therefore isolated pa-
tients, impact patient care and burden the healthcare sys-
tem [5-7]. The duration of MRSA and VRE colonization
has previously been assessed in mostly small studies.
Thus, pooling of these data might provide a better under-
standing of the natural history of colonization and the
timing of clearance and thereby inform clinical care and
public policy. We performed a systematic review of ran-
domized controlled trials and observational studies that
followed patients with a history of MRSA and VRE
colonization and assessed study characteristics and study
quality. In the absence of individual data, we pooled
study-level data to calculate estimates of time to clearance
of colonization.
Methods
Search strategy
We conducted two separate computerized searches in
OVID Medline to identify relevant English-language
studies including adults and published between January
1990 and July 2012. Index searches included MeSH terms
for MRSA: “methicillin-resistant Staphylococcus aureus”
or “methicillin resistance” and “colonization” or “carrier
state”. For VRE, search terms included ”vancomycin resist-
ance” and “Enterococcus faecalis” or “Enterococcus” or “En-
terococcus faecium” and “colonization” or “carrier state”.
Inclusion criteria required that a study define a population
of MRSA or VRE carriers and subsequently perform at
least one screening for colonization status in the absence
of treatment or decolonization therapy for MRSA or VRE.
Included studies provided the number of subjects cleared
within a defined time period. The searches and subse-
quent study selection were conducted separately for
MRSA and VRE.
Study selection
Two authors (ESS and MLP) independently reviewed the
abstracts of publications identified by the two searches.
Publications that addressed the length of time subjects
with a history of infection or colonization remained col-
onized or included evidence that patients were followed
over time underwent full-text review for determination
of inclusion and data extractionf r o mt h o s et h a tm e ti n c l u -
sion criteria. Studies with no abstract or for which it was
not possible to determine if the publication contained data
meeting inclusion criteria also underwent full-text review.
Colonization in both study selections was defined as
having a positive culture or nucleic acid amplification
assay (for MRSA or VRE) without evidence for active
infection. Studies were required to report on screening
from at least one anatomical site; any anatomical site for
screening was permitted for inclusion. While clearance
was defined by each study individually, at least one
microbiological result supporting clearance was required
for inclusion. For studies reporting more than one time-
point of documented clearance, the latest time-point
was included in the analysis. A third author (DCH) me-
diated any differences in interpretations regarding inclu-
sion/exclusion.
Data extraction
For studies meeting inclusion criteria for both searches,
the following data were extracted: authors, study design,
country, years of study, subject description, anatomic
screening site, screening method (i.e., culture, molecular
diagnostics), follow-up period (weeks), total number of
subjects, number of subjects lost to follow-up, study-
defined clearance, time to documented clearance for those
who cleared (weeks) and the proportion of subjects with
documented clearance. The role of antibiotic exposure
with respect to the duration of colonization was assessed,
if documented. Data were entered separately for the
MRSA and VRE studies into standardized forms and veri-
fied in duplicate for consistency and accuracy. For VRE, it
was noted if studies made a distinction between E. faecalis
and E. faecium.
Statistical methods
For both MRSA and VRE analyses, we collected informa-
tion about the total sample size and number or percentage
of subjects with documented clearance of colonization and
the corresponding time after documented colonization at
which the assessment of clearance was made for each in-
cluded study. For studies that did not provide details on
loss to follow-up, the number of clearance events was
calculated as the product of the percent clearance times
the total sample size. We conservatively assumed that
all reported clearance events happened at the time-
point reported by the study and not before.
For both MRSA and VRE analyses, we used Greenwood’s
formula to estimate the standard error of each study’sr e -
ported decolonization rate [8]. This approach allowed for
the generation of MRSA and VRE “champagne plots” of
the reported rates of colonization clearance, where the size
of each study’s data point is inversely proportional to its
standard error. For the MRSA and VRE studies, we then
separately fitted logistic regression models to assess the
relationship between the proportion of patients with
documented spontaneous clearance and the time since
documented colonization. In parallel sensitivity ana-
lyses, we examined the relative influence of each study
on the estimated median time to clearance. To do so,
we used a jackknife method whereby each study, within
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tially removed from the dataset, and the median time to
documented clearance was recalculated. Given the de-
pendence of the analysis on the duration of follow-up, in a
second set of sensitivity analyses, we restricted the MRSA
studies to include only those that reported clearance on or
before the maximum observed follow-up time for the in-
cluded VRE studies. We then subsequently recalculated
the median time to documented MRSA clearance with
this restriction in place.
Quality assessment
Cohort studies were assessed for quality using a modifica-
tion of the Newcastle-Ottawa Quality Assessment Scale
(NOS) developed specifically for the purposes of this re-
view. The assessment was performed independently (ESS,
MLP), with any disagreements resolved by a third author
(DCH). Beyond meeting inclusion criteria for the review,
the quality of randomized controlled trials included in the
analyses was not assessed.
The standard NOS for cohort studies contains eight
questions that assess study quality based on subject selec-
tion, comparison and outcome validation. This assessment
evaluates studies on a maximum nine-point scale based
on the representativeness of the exposed and non-exposed
cohorts, ascertainment of exposure, comparability of the
cohorts, assessment of outcome and appropriate follow-
up time and loss to follow-up [9]. In the modified scale,
we similarly addressed these quality measures. Selection
and comparability quality was assessed by a demographic
comparison between colonized and cleared subjects. As-
certainment of exposure and outcome was determined by
recording whether colonization (exposure) and clearance
of colonization (outcome) were determined using standard
microbiological methods, and whether the study provided
information about the length of time to documented clear-
ance. Finally, the standard NOS records how long subjects
were followed for outcomes assessment and loss to
follow-up; in the modified NOS, we used a cutoff of three
or more months of follow-up, and loss to follow-up of less
than 30%. Of note, in the standard NOS, one of the key
quality measures is demonstration that the outcome of
interest was not present at the start of the study. For this
systematic review, the outcome of interest was clearance
of colonization. By definition, subjects who were not
colonized at the start of the study were excluded since
all subjects needed to be colonized in order to achieve
the outcome of interest.
Results
MRSA
MRSA study identification
The MRSA search criteria identified 981 non-duplicate
publications. Full-text review was completed for 234
publications, and each was reviewed in detail for final
determination of inclusion and for data extraction
(Figure 1). This procedure resulted in a total of 16 studies
with 1,804 non-duplicated subjects included in the review,
and 13 cohort studies included in the quality assessment
(Figure 1) [10].
MRSA study characteristics
The 16 studies were diverse in design, geographic site,
enrollment period, anatomic screening site, and patient
location (Table 1) [11-26]. The median duration of total
follow-up was 38 weeks.
For studies that included hospitalized patients, data were
more frequently not provided about the subjects’ residence
prior to admission (i.e., home versus facility). Fourteen of
16 studies sampled subjects at least three months after
documented colonization. For loss to follow-up, seven
studies had less than 30%, four had more than 30%, and
five provided no information.
MRSA clearance rates
Reported clearance rates ranged from 12% [21] to 79%
[23]. The time to observed clearance ranged from one
[26] to 208 weeks [23]. A plot of the percentage of sub-
jects documented to have cleared MRSA colonization
over time demonstrates a trend toward the majority of
subjects clearing colonization over the follow-up periods
reported (Figure 2). Using logistic regression, we found
that 50% of patients cleared colonization at 88 weeks
after initial documentation of colonization. At one, two,
three and four years after initial determination of MRSA
colonization, the model-estimated proportions of sub-
jects with documented clearance of colonization were
41, 54, 66, and 77%, respectively. Comparing the patient
populations represented, long-term care, hospitalized,
and ambulatory, at 26 weeks after initial documentation
of colonization, the model-fitted percentages of those
clearing were significantly different at 22, 36, and 68%,
respectively (P<0.0001).
The majority of studies did not provide enough infor-
mation to determine if the cohorts of colonized or cleared
subjects were similar. However, three studies [14,22,25]
did provide these data, and in general the demographic
characteristics of the subjects in the colonized and
cleared groups from each cohort were similar, with
some notable exceptions. Scanvic reported residence at
another healthcare institution and break in the skin to
be significantly associated with persistent carriage (32%
vs 11% and 67.7% vs. 28%, respectively). Lucet found as-
sistance with activities of daily living (ADLs) to be sig-
nificantly different between the groups (57.5% vs. 49.3%,
respectively). Manzur reported the presence of decubi-
tus ulcers to be a risk factor for persistent colonization
(27.5% vs. 13.7%, respectively).
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but two studies ([25], Study “O” and [23], Study “M”), the
estimated median time to documented clearance would
change only minimally if each study was excluded. The ex-
clusion of Manzur [25] resulted in a model-fitted median
time to clearance of 68 weeks. Separately, the exclusion of
Robicsek [23] resulted in a model-fitted median clearance
time >172 weeks after documented colonization.
The impact of antibiotic exposure on persistence of
colonization was either not reported or found to have no
significant association with duration of colonization for
the majority of studies. Only one study reported that anti-
biotic exposure in colonized patients was significantly
associated with persistence of colonization [18].
MRSA study quality
The 13 cohort studies were assessed using the modified
NOS. Of these, only Lucet [22] met all quality criteria
based on the modified NOS. The remainder of the studies
were missing quality criteria in either comparability, ap-
propriate time to follow-up or loss of follow-up; overall,
these studies were of moderate quality, with the mean
score of 4.8/6 (range 3–6). As the NOS results lacked vari-
ation and were applicable only to cohort studies, they
were not used as weights in the pooled analyses.
VRE
VRE study identification
The search criteria identified 278 non-duplicate screened
publications. Full-text review was completed for 108 pub-
lications, all of which were reviewed in detail for final
determination of inclusion and data extraction. This
procedure resulted in 13 studies included in the review,
and 12 cohort studies included in the quality assessment
(Figure 3) [10].
VRE study characteristics
The 13 included studies, including a total of 1,936 non-
duplicated patients varied in design, geographic site, en-
rollment period, and anatomic screening site; the vast
majority included hospitalized patients (Table 2) [27-39].
The median duration of total follow-up was 25 weeks.
Seven of the 13 studies reported on E. faecium alone,
982 records identified through 
database searching
981 records after duplicates removed
and screened for possible inclusion
747 excluded after screening 
of abstract and title (inclusion 
criteria not met)
234 full-text articles 
assessed for eligibility
218 excluded
99 had missing data
90 were studies of 
general screening for 
infection or treatment
15 were case reports 
14 were decolonization
protocols
16 studies assessing the 
duration of MRSA 
colonization included in 
quantitative synthesis 
(meta-analysis)
Figure 1 Study selection process (MRSA).
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Author
year [ref]
Study
ID
Design Country Year of
study
Subject
description
Screening site Screening
method
Latest
documented
follow up
(weeks)
N Lost to
follow
up (N)
Clearance
defined
Weeks to
documented
clearance
% cleared
Sanford
1994 [11]
A Retrospective
cohort
USA 1989-1991 Hospitalized
patients
Nares, axillae,
perineum/ groin,
wound, sputum,
tracheal aspirate
CX; T 240 36 * 2 negative CX 172 50%†
Mulhausen
1996 [12]
B Prospective
cohort
USA 1991-2 Residents at
LTCFs
Nares CX 52 47 34 1 negative CX on
two separate
samplings
52 13%
O’Sullivan
2000 [13]
C Prospective
cohort
Ireland 1994-5 Residents at
LTCFs
Nares, throat, hairline,
axillae, groin,
perineum, skin lesions
CX; T 39 65 14 1 negative CX 26 49%
Scanvic
2001 [14]
D Prospective
cohort
France 1998 Hospitalized
patients
Nares, skin, axillae,
groin
CX; T 36 (a) 78 * 4 negative CX
obtained from 2
sites
37 50%†
Ellis 2004
[15]
E Prospective
cohort
USA 2003 US Army
personnel
Nares CX; T 13 24 * 1 negative CX 9 67%
Cretnik
2005 [16]
F Prospective
cohort
Slovenia 2001-2 Residents and
HCW at LTCFs
Nares, skin lesions,
axillae, groin
CX; T 13 12 2 2 negative CX from
2s i t e so n3s e p a r a t e
samplings
13 33%
Vriens 2005
[17]
G Prospective
cohort
Netherlands 1991-2001 Hospitalized
patients
Nares, throat,
perineum, wounds,
skin lesions, urine and
sputum
CX; PCR 104 57 21 All negative CX
from up to 7 sites
on 3 separate
samplings
104 46%
Marschall
2006 [18]
H Retrospective
cohort
Switzerland 2000-3 Hospitalized
patients
Nares, groin, skin
lesions, tracheal
secretions, urine
CX; T 231 80 * All negative CX
from up to 6 sites
on 2 separate
samplings
85 50%†
Ellis 2007
[19]
I RCT USA 2005 US Army
personnel
Nares CX; T 16 66 1 1 negative CX 16 64%
Simor 2007
[20]
J RCT Canada 2000-3 Hospitalized
patients
Nares, perineum, skin
lesions, catheter sites
CX; T 34 35 26 1 negative CX on 2
separate samplings
13 23%
Wendt 2007
[21]
K RCT Germany 2001-4 Hospitalized
patients and
residents at
LTCFs
Nares, throat, groin,
perineum, skin defects,
any previously
colonized site
CX; T 13 58 3 All negative CX at
up to 7 sites on 5
separate samplings
4 12%
Lucet 2009
[22]
L Prospective
cohort
France 2003-4 Hospitalized
patients
discharged to
home care
Nares, chronic skin
lesions
CX 52 148 44 1 negative CX on 2
separate samplings
52 51%
Robicsek
2009 [23]
M Retrospective
cohort
USA 2006-7 Hospitalized
patients
Nares PCR 208 824 * 1 negative PCR 208 79%
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Lautenbach
2010 [24]
N Prospective
cohort
USA 2008 Ambulatory
patients and
household
contacts
Nares, axilla, throat;
groin and perineum
CX; PCR; T 14 11 0 All negative cultures
from up to 5 sites
on 6 separate
collections
14 73%
Manzur
2010 [25]
O Prospective
cohort
Spain 2005-7 Residents at
LTCFs
Nares, decubitus ulcers CX; T 77 231 104 1 negative CX on 2
separate collections
77 27%
Van Velzen
2011 [26]
P Retrospective
cohort
Scotland 2010 Hospitalized
patients
Nares, perineum,
axillae, throat, wounds
and devices
CX; PCR; T 4 32 0 All negative cultures
from up to 6 sites
on 2 separate
occasions
1 25%
(a) Follow up at least 13 weeks since hospitalization; median clearance at 37 weeks reported; mean time since hospital discharge 36 weeks.
*Not documented; † Kaplan Meier estimates which do not provide information on those lost to follow up.
HCW: health care worker; LTCF: long term care facility; MRSA: methicillin resistant Staphylococcus aureus; N: number; CX: culture; T: typing of strain performed; PCR: polymerase chain reaction; RCT: randomized
controlled trial.
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and E. faecium.
VRE clearance rates
Reported time to clearance ranged from one [32] to
43 weeks [37], with documented clearance rates of zero
[30] to 84% [37]. A plot of the percentage of subjects doc-
umented to have cleared VRE colonization over time
demonstrates a trend toward the majority of subjects
clearing colonization during the period of observation
(Figure 4). Using logistic regression, we found that 50% of
subjects cleared colonization at 25 weeks after initial
documentation of colonization. At 10, 20, 30 and 40 weeks
after initial determination of VRE colonization, the model
estimated that 19, 38, 61, and 80% of subjects had docu-
mented clearance of colonization, respectively. Since the
vast majority of subjects were hospitalized patients, we
were unable to assess the effect of patient population type
(inpatient versus LTCF resident) on time to documented
clearance.
Only two of the studies included, Park [38] and Yoon
[39] provided sufficient demographic data to formally
evaluate variables associated with either persistence or
clearance of colonization. Park [38] found three variables,
age (odds ratio [OR]: 0.99; P=0.05), duration of glycopep-
tide use prior to VRE positivity (OR: 2.16; P=0.003), and
length of hospital stay (OR 1.01; P=0.001) associated with
subjects having three consecutive negative rectal cultures.
Mean duration of glycopetide use was reported with
respect to hemodialysis; patients on chronic HD were
observed to be exposed to 12.7 days while patients on
non-chronic HD were observed to be exposed to 4.5 days
(P=0.001). Yoon [39] compared subjects who cleared
colonization early (< three weeks) to those who cleared
later (≥ five weeks) and found that they differed on several
characteristics. The early group was more likely to be
younger (P=0.01) and to have a shorter length of stay in
an ICU (P=0.03). This group was also less likely to have
had prior exposure to medical devices, including central
venous catheters and endotracheal intubation (P=0.04
and P=0.04, respectively), and less likely to have received
selected antibiotics after colonization, including carbapen-
ems (P =0.01), vancomycin (P <0.001), or fluoroquinolones
(P=0.04). In multivariable logistic regression analysis,
they found that vancomycin use after VREF colonization
was significantly associated with prolonged carriage (OR
4.1; P=0.02).
Unlike for the MRSA analysis, the VRE jackknife sensi-
tivity analysis revealed that the estimated median time to
documented clearance did not appear substantially differ-
ent with the exclusion of any one study.
Antibiotic exposure was reported to be significantly
and positively associated with longer duration of carriage
in several of the studies [28,34,39], however others found
no such association [33,36,38]. The remaining studies
did not report on the relationship.
VRE study quality
The 12 cohort studies were assessed using the modified
NOS. No study fulfilled all quality criteria for the modified
NOS; the majority were of moderate quality with the
mean score of 4.6/6 (range 3–5). As the NOS results
lacked variation and were applicable only to cohort
studies, they were not used as weights in the pooled
analyses.
Comparison of MRSA and VRE pooled clearance rates
Clearance rates for MRSA and VRE were compared by
restricting the time to follow-up for the MRSA studies
to the maximum observed time point for VRE studies
(43 weeks). Figure 5 shows that with this restriction,
which results in the exclusion of five studies (A, G, H, L, M)
and the inclusion of earlier-reported time intervals from
two studies (Manzur, “O1” and Mulhausen, “B1”), the
model-fitted median time to documented clearance would
occur at 41 weeks.
Discussion
We reviewed the published literature on the natural his-
tory of MRSA and VRE colonization. There is substantial
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Figure 2 Analysis of median time to documented clearance of
MRSA colonization. The X-axis represents time (in weeks) from
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of patients with documented clearance of colonization. This proportion
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Each circle represents a single study (A-P). The size of the circle is
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geneity both identifies a clear need for further investi-
gation and tempers our interpretation of the pooled
estimates of time to clearance of colonization. Based on
the studies meeting our inclusion criteria, our system-
atic review demonstrates that persistent colonization
decreases over time, with clearance of colonization in
half of patients at 88 weeks for MRSA and 26 weeks for
VRE.
While the weight of the existing data, and clinical
experience, suggest that clearance of MRSA and VRE
colonization increases over time, precision around the
time to clearance is not possible due to the major limita-
tions of the studies in this domain. These limitations not
only hinder our interpretation of the pooled findings,
but also highlight the need for additional studies. Lack
of a consistent definition of clearance, uncertainty re-
garding the time of initial colonization, variation in fre-
quency of sampling for persistent colonization, and
variation in duration of follow-up and loss to follow-up
all impose substantial constraints on our interpretation
of the median time to clearance.
Because subjects are not screened prospectively and
continuously, the initial date of colonization is assumed
to be the time MRSA or VRE were discovered and docu-
mented (based on either a clinical infection or a surveil-
lance screening). There is almost certainly variation in the
lag time between actual colonization and the identification
of a subject as being colonized. Under these inevitable
circumstances, calculations of duration of colonization
m a yu n d e r e s t i m a t et h et r u ed u r a t i o no fc o l o n i z a t i o n
and the pattern of clearance. On the other hand, if the
time interval between initial documentation of colonization
and re-screening is prolonged, duration of colonization
may also be overestimated. A striking observation from
the combined reviews is the relatively short time to
clearance for VRE, as compared to MRSA. The longer
median time to clearance estimated for MRSA is in part
a reflection of the length of follow-up, as evidenced by
the reduction from 88 weeks to 41 weeks observed
when follow-up was restricted to the same duration as
the VRE studies.
We did not impose a universal definition of clearance
as a prerequisite for inclusion in our review, and across
284 records identified through 
database searching
278 records after duplicates removed
and screened for possible inclusion
170 excluded after screening 
of abstract and title (inclusion 
criteria not met)
108 full-text articles 
assessed for eligibility
95 excluded
39 had missing data
50 were studies of 
general screening for 
infection or treatment
4 were decolonization 
protocols
1 were case reports 
1 unrelated to VRE 
colonization 13 studies assessing the 
duration of VRE
colonization included in 
quantitative synthesis 
(meta-analysis)
Figure 3 Study selection process (VRE).
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Author
year [ref]
VRE Study
ID
Design Country Year of
study
Subject
description
Screening
site
Screening
method
Latest
documented
follow up
(weeks)
N Lost to
follow
up (N)
Clearance defined Weeks to
documented
clearance
%
cleared
Montecalvo
1995 [27]
VREF A Prospective
cohort
USA 1993-4 Hospitalized
patients
Perianal CX; T 18 86 50 1 negative CX on admission
and weekly negative culture
during admission
18 2%
Brennen
1998 [28]
VREF B Prospective
cohort
USA 1993-4 Residents in
LTCFs
Rectal CX 25 36 * 2 negative CX on 2 separate
samplings
10 50%†
Goetz 1998
[29]
VREF C Prospective
cohort
USA 1994-6 Hospitalized
patients
Rectal or
stool
CX * 210 61 1 negative CX on 2 separate
samplings
14 40%†
Bhorade
1999 [30]
ND D Prospective
cohort
USA 1996-8 Hospitalized
patients
Rectal or
stool
CX 2 10 6 1 negative CX on 5 separate
samplings
N/A 0%
Weinstein
1999 [31]
VREF E Prospective
cohort
Canada 1995 Hospitalized
patients
Rectal CX 25 24 0 1 negative CX on at least
3 separate samplings
25 38%
D’Agata
2001 [32]
ND F Prospective
cohort
USA 1998 Hospitalized
patients
Rectal CX 3 13 6 1 negative culture on
at least 2 separate samplings
18 %
Wong 2001
[33]
ND G RCT USA * Hospitalized
patients and
residents of
LTCFs
Rectal CX 3 24 4 1 negative CX on 3 separate
samplings
3 21%
Byers 2002
[34]
ND H Retrospective
cohort
USA 1994-6 Hospitalized
patients
Rectal CX; T 86 116 0 1 negative CX on 3 separate
samplings
22 64%
Hachem
and Raad
2002 [35]
VREF I Prospective
cohort
USA 1997 Hospitalized
patients
Stool CX 13 28 0 1 negative CX on at least 2
separate samplings
13 4%
Mascini
2003 [36]
VREF J Prospective
cohort
Netherlands 2000 Hospitalized
patients
Rectal CX; PCR;T 26 11 (a) * 3 negative CX on at least 3
separate samplings
6 50%†
Huang 2007
[37]
ND K1 Retrospective
cohort
USA 2002-4 Hospitalized
patients
Rectal CX; PCR (b) 52 394 (c) * 1 negative CX 9 24%
Huang 2007
[37]
ND K Retrospective
cohort
USA 2002-4 Hospitalized
patients
Rectal CX; PCR (b) 52 126 (d) * 1 negative CX 43 84%
Park 2011
[38]
ND L1 Retrospective
cohort
South
Korea
2003-10 Hospitalized
patients on
chronic HD
Rectal CX 39 89 20 1 negative CX on 3 separate
samplings
16 10%
Park 2011
[38]
ND L Retrospective
cohort
South
Korea
2003-10 Hospitalized
patients on non-
chronic HD
Rectal CX 35 723 339 1 negative CX on 3 separate
samplings
9 12%
Yoon 2011
[39]
VREF M Retrospective
cohort
South
Korea
2006-9 Hospitalized
patients
Rectal CX 19 58 * 1 negative CX on 3 separate
samplings
19 28%
(a) Only patients with non-epidemic strain were included in analysis. (b) One of four participating sites used both culture and PCR; the others used culture only. (c) Subset of patients admitted ≤ 60 days from last
known positive culture. (d) Subset of patients admitted > 300 days from last known positive culture.
*Not documented; † Kaplan Meier estimates which do not provide information on those lost to follow up.
HCW: health care worker; HD: Hemodialysis; LTCF: long term care facility; VRE: vancomycin resistant enterococcus; VREF: E. faecium; ND: no distinction made between E. faecalis and E faecium; N: number; CX: culture;
T; strain typing performed; PCR: polymerase chain reaction; RCT: randomized controlled trial.
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7studies, the definition of clearance varied in part due to the
absence of guidelines that define clearance of colonization
[40]. The diversity of results that were considered evidence
of clearance across the studies is a reflection of the lack
of consensus on this point, and limits our interpretation
of the pooled estimates. The frequency of re-sampling
and duration of follow up varied as well. These factors
would be expected to affect reported time to clearance
and thus add reasons to be cautious in the interpret-
ation of the systematic review. Several of the MRSA
studies [11,14,18,22,23,25] showed an initial brisk de-
cline in colonization followed by a stabilization of the
pool of colonized (in those studies following patients for
extended periods), supporting the general consensus
that there are likely sub-groups among colonized pa-
tients including those who are transiently, intermittently
or persistently colonized. While some of the studies did
make such distinctions, again, the definition of each
carrier-state varied.
Beyond the concepts of transient, intermittent or per-
sistent colonization, isolates identified in the screening
studies may represent an initial colonizing strain or a
second (or third) isolate. Some studies performed add-
itional analysis to identify strain types. In the absence of
strain-typing, it is not possible to conclude that a patient
who remains persistently colonized is in fact colonized
with the endogenous strain, or intermittently colonized
with different strains. From the perspective of infection
control implementation, such distinctions may not be
meaningful in terms of the practical implementation of
CP measures, and those cases in which cohorting is per-
mitted [40,41]. Given currently available assays, docu-
mented clearance of colonization may in fact represent a
level of colonization below the limits of detection (with
the same strain or different strain).
A conceptual limitation of our review relates to
colonization dynamics and specifically the clearance of the
colonizing strain or re-colonization with a new strain,
which may be particularly relevant in the setting of select-
ive antibiotic pressure. In the VRE analysis, one clinical
variable, prior antibiotic use, was associated with a trend
toward early clearance of colonization, supporting the ob-
servation that concurrent antibiotic therapy affects the
sensitivity of surveillance cultures for VRE [42,43]. The
issue of test sensitivity is particularly relevant in the set-
ting of selective antibiotic pressure, as has been demon-
strated in the case of VRE [44-47]. A detailed analysis of
the impact of antibiotics on colonization dynamics was
not directly within the scope of the study, however, is an
important area for further investigation, especially with
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Figure 4 Analysis of median time to documented clearance of VRE colonization. The X-axis represents time (in weeks) from documented
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subject population minus those lost to follow-up. Each circle represents a single study (A-M). The size of the circle is inversely proportional to its
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http://www.biomedcentral.com/1471-2334/14/177respect to VRE. In the VRE studies included in this review,
the lack of universal definitions of clearance and carriage-
type again limit our interpretation. Finally, the years in-
cluded span close to 20 years for both MRSA and VRE,
during which changes in epidemiology, screening prac-
tices, and technology have taken place, raises challenges
for comparison across studies and interpretation of the
pooled clearance estimates.
Additional limitations are second-order compared to
the fundamental deficiencies described above. Most stud-
ies provided insufficient details regarding the demographic
characteristics of subjects who cleared versus those who
remained persistently colonized. However, one demo-
graphic variable for MRSA-colonized patients, ambula-
tory patient status versus inpatient or LTCF patient
status, was associated with a trend toward early clear-
ance of colonization in three studies. It is possible that
the persistence of colonization in hospitalized and LTCF
patients may be the result of re-colonization. Based on
our quality assessment of cohort studies, the majority
were of moderate quality.
Our analysis was also limited by the use of aggregate
data rather than patient-level data, which would have
permitted a survival analysis approach. Most studies
screened using microbiological methods that relied on
standard culture techniques. Although molecular assays
are more costly on a per-test basis, their greater sensitiv-
ity may allow reduction in repetitive testing and more ef-
fective implementation [48]. Additional research employing
molecular methods in studies of the natural history of
colonization is needed. Even with the more widespread
use of molecular assays however, it is still possible that
colonized patients may fail to be identified, if the level of
colonization is below the limit of the sampling methods.
In terms of practical implications of false negative screens,
patients with low levels of colonization may pose a lower
transmission risk. Finally, we are not able to address the
risk of publication bias in the inclusion of studies.
Conclusions
Our study is the first systematic review to address the
topic of time to clearance of MRSA and VRE colonization.
Our review highlights a substantial degree of heterogen-
eity across the studies, beyond those common in such
analyses. The fundamental differences across studies in-
cluding definition of clearance of colonization, frequency
of sampling, assays implemented and duration of follow
up, highlight the gaps in the available data and caution the
interpretation of estimates of clearance derived from pool-
ing the studies included. Despite the strengths and weak-
nesses of the existing literature and the methodological
challenges of interpreting pooled results across a hetero-
geneous group of studies, the data suggest a decline in
colonization over time. While there is uncertainty about
the complete duration of colonization, the types of data in
the included studies are those generally available in clin-
ical settings and thus can set a time frame for clearance in
most patients. The analysis presented brings to the fore
the inconsistencies with infection control policies that as-
sume colonization is life-long.
The duration of colonization has important implica-
tions for patient care, infection control policy, and re-
source utilization. Once a patient is known to have a
clinical infection or to be colonized with MRSA or VRE,
he or she is usually placed on contact precautions (CP)
based on guidelines from the Centers for Disease Con-
trol and Prevention (CDC) [41]. Many institutions docu-
ment such patients as MRSA or VRE carriers, so that on
readmission they are again placed on CP. CDC has not
provided guidance on when or under what testing cir-
cumstances CP may be discontinued, resulting in nation-
wide variation in policies and procedures regarding the
duration of CP for MRSA and VRE [49]. If patients la-
beled as carriers have in fact cleared colonization, they
are likely exposed to the various adverse consequences
of CP with additional costs [5,6,50-56].
Further research is needed to address the lag time from
initial colonization to documented colonization and to ad-
dress the issue of sampling bias (both frequency and dur-
ation of follow-up). Prospective studies of the natural
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Figure 5 Analysis of median time to documented clearance of
MRSA colonization, restricted follow-up period. The X-axis represents
time (in weeks) from documented colonization and the Y-axis represents
the proportion of patients with documented clearance of colonization.
This proportion included the initial subject population minus those lost
to follow-up. Each circle represents a single study as in Figure 2,
excluding studies A, G and H). The size of the circle is inversely
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clearance over time, with 50% of subjects clearing MRSA at 41 weeks
from time of documented colonization (*).
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http://www.biomedcentral.com/1471-2334/14/177history of colonization, based on consensus definitions of
colonization and clearance, are needed. Such studies will
be critical for informing screening policies for identifying
those patients no longer colonized with MRSA or VRE and
to support guidelines on duration of contact precautions.
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